About us

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Industry
Biotechnology Research
Company size
11-50 employees
Type
Privately Held
Founded
2020

Employees at Appia Bio

Updates

Similar pages

Browse jobs

Funding

Appia Bio 1 total round

Last Round

Series A

US$ 52.0M

See more info on crunchbase